<DOC>
	<DOCNO>NCT02732119</DOCNO>
	<brief_summary>The purpose study determine triplet combination ribociclib , everolimus exemastane effective treatment locally advanced/metastatic breast cancer follow treatment CDK 4/6 inhibitor</brief_summary>
	<brief_title>Study Ribociclib With Everolimus + Exemestane HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression CDK 4/6 Inhibitor .</brief_title>
	<detailed_description>The purpose phase I dose escalation part study estimate MTD ( ) and/or identify RP2D combination treatment ribociclib+ everolimus + exemestane dose continuously adult men postmenopausal woman HR+ HER2-negative advance breast cancer resistant non-steroidal aromatase inhibitor , fulvestrant tamoxifen . The purpose phase II portion trial evaluate anti-tumor activity exemestane , everolimus ribociclib triplet follow progression CDK 4/6 inhibitor . This part study conduct use Simon 's optimal two-stage design .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult men woman Patient confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory HER2negative breast cancer Patient must either measurable disease RECIST 1.1 bone lesion absence measurable disease . ECOG Performance Status 0 1 Disease refractory either , AI , tamoxifen fulvestrant Previously treat CDK 4/6 inhibitor . Patient adequate bone marrow organ function . Patient symptomatic visceral disease disease burden make patient ineligible endocrine therapy per investigator 's best judgment . Patient receive one line chemotherapy advance disease . Previous treatment mTOR inhibitor , exemestane advance disease . Progressed one CDK 4/6 inhibitor Patient CNS involvement unless least 4 week prior therapy completion . Clinically significant , uncontrolled heart disease and/or recent cardiac event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>ribociclib</keyword>
	<keyword>everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>exemestane</keyword>
	<keyword>Aromasin</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>